Written by: Darren Candow, Diego A. Bonilla and Richard B. Kreider 

IN THIS ARTICLE

1. Introduction
2. What the evidence shows in older adults
3. A gap in the evidence
4. Why creatine might work
5. The bottom line
6. Safety and dosing

Sarcopenia, the loss of muscle mass, strength, and function, affects roughly 10% of adults over 60, or about 50 million people worldwide. It increases the risk of falls, frailty, hospitalization, and loss of independence. Current clinical guidelines consistently recommend adequate protein intake and vitamin D supplementation when deficient, alongside structured resistance exercise. But these strategies alone do not fully stop the progressive decline.

This is where creatine monohydrate enters the conversation; not as a magic bullet, but as one more tool in a comprehensive toolbox. 

What the evidence shows in older adults

Creatine monohydrate is one of the most studied nutritional supplements in the world. In older populations, systematic reviews and meta-analyses consistently show that creatine, particularly when combined with resistance exercise, improves whole-body lean mass, limb muscle thickness and density, muscle strength, and functional ability compared to placebo.

A recent update to a previous meta-analysis, including 792 older adults across 18 studies, found that creatine combined with resistance exercise increased lean mass by 1.18 kg (95% CI: 0.75 to 1.62 kg) compared to placebo plus resistance exercise (Figure 1). The evidence is strongest for upper-body strength; results for lower-body strength are mixed across studies.

 

Figure 1. Forest plot of studies investigating effects of creatine monohydrate (CrM) and placebo during resistance exercise on lean mass. Positive values indicate an effect favoring creatine monohydrate supplementation.

The European Food Safety Authority (EFSA) has concluded that a cause-and-effect relationship exists between creatine intake (3 g/day) combined with resistance exercise and improved muscle strength in adults over 55. Importantly, this regulatory opinion applies to healthy older adults, not specifically to those diagnosed with sarcopenia.

A gap in the evidence

Here is a crucial point: most creatine research has been conducted in healthy older adults, not in those formally diagnosed with sarcopenia. Only a handful of small studies have specifically evaluated creatine in sarcopenic individuals, and some are descriptive case reports rather than large randomized trials.

In one small study of four sarcopenic older women, 24 weeks of creatine plus resistance exercise reversed the sarcopenia diagnosis in two participants. In another, 32 weeks of supplementation eliminated the pre-sarcopenic classification in several participants. These findings are promising but preliminary. Adequately powered trials in sarcopenic populations are urgently needed.

Why creatine might work

The primary mechanism is energy availability. Sarcopenic older adults have lower muscle phosphocreatine stores and slower post-exercise phosphocreatine recovery. Creatine supplementation increases intramuscular phosphocreatine, which supports higher training volume and intensity, the very stimulus needed to build and preserve muscle.

Other proposed mechanisms (such as increased satellite cell activity, enhanced protein synthesis signaling, or reduced inflammation) have less consistent support in older adults. Most of this mechanistic evidence comes from younger populations and cannot be directly generalized.

The bottom line

Creatine monohydrate is not a stand-alone treatment for sarcopenia. But when combined with resistance exercise, adequate protein, and appropriate medical care, it can help preserve lean mass, strength, and functional ability in older adults. The evidence in healthy older adults is robust; the evidence in those already diagnosed with sarcopenia is promising but still emerging.

For now, creatine deserves a place in the conversation about healthy aging; not as a cure, but as a practical, safe, and affordable adjunct to the strategies we already know work.

Safety and dosing

Creatine monohydrate has a strong safety profile in healthy older adults. The U.S. Food and Drug Administration granted it GRAS (Generally Recognized as Safe) status in 2020. Randomized trials lasting up to two years, with doses around 10 g/day, have shown no clinically meaningful adverse effects on kidney or liver function in healthy older adults. 

    • Practical dosing: 3 to 5 grams per day is sufficient for most older adults. A loading phase (20 g/day for 5–7 days) is optional and not necessary. Creatine should be taken consistently, ideally with a meal or protein shake to support uptake.

    • Minor gastrointestinal symptoms or muscle cramps have been reported occasionally, but these are generally mild and not severe enough to affect adherence.

Read our new article:

Candow, D. G., Traxler, S., Chilibeck, P. D., Forbes, S. C., Ostojic, S. M., Stout, J. R., Antonio, J., Kreider, R. B., Bonilla, D. A., Roberts, M. D., Tarnopolsky, M. A., Angelini, F. & Fabiano, N. (2026). Creatine monohydrate supplementation: one tool in the toolbox for treating sarcopenia. Longevity, 7(1). https://doi.org/10.1080/30653495.2026.2727350

 


About the authors

Prof. Darren Candow, PhD
He is a Full Professor, Past Associate Dean-Graduate Studies and Research and supervises the Aging Muscle and Bone Health Laboratory in the Faculty of Kinesiology & Health Studies, University of Regina. View the full author profile →

Prof. Diego A. Bonilla, MSc
Senior Researcher (MinCiencias Colombia #957 SNCTI). CEO & Scientific Director at DBSS. Interested in understanding adaptation in complex systems under the allostasis-interoception paradigm. View the full author profile →

Prof. Richard B. Kreider, PhD
Professor and Director of the Exercise & Sport Nutrition Lab and Director of the Human Clinical Core at Texas A&M University. He has conducted numerous studies on the role of exercise and nutrition on health, performance, disease and rehabilitation. View the full author profile →